Completed PHASE3 INTERVENTIONAL 2-arm NCT04109976

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Sponsor: UCB Biopharma SRL

Conditions Psoriatic Arthritis

Interventions Bimekizumab

Updated 24 times since 2019 Last updated: Nov 29, 2023 Started: Aug 13, 2019 Primary completion: Nov 5, 2020 Completion: Nov 13, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Psoriatic Arthritis and is currently completed. UCB Biopharma SRL leads this study, which shows 24 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

24 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2023 — Jul 2024 [monthly]

Completed PHASE3
Sep 2022 — Dec 2023 [monthly]

Completed PHASE3

▶ Show 19 earlier versions

Apr 2022 — Sep 2022 [monthly]

Completed PHASE3
Dec 2021 — Apr 2022 [monthly]

Completed PHASE3
Mar 2021 — Dec 2021 [monthly]

Completed PHASE3
Feb 2021 — Mar 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Nov 2020 — Dec 2020 [monthly]

Enrolling By Invitation PHASE3
Oct 2020 — Nov 2020 [monthly]

Enrolling By Invitation PHASE3
Sep 2020 — Oct 2020 [monthly]

Enrolling By Invitation PHASE3
Aug 2020 — Sep 2020 [monthly]

Enrolling By Invitation PHASE3
Jul 2020 — Aug 2020 [monthly]

Enrolling By Invitation PHASE3
Jun 2020 — Jul 2020 [monthly]

Enrolling By Invitation PHASE3
May 2020 — Jun 2020 [monthly]

Enrolling By Invitation PHASE3
Apr 2020 — May 2020 [monthly]

Enrolling By Invitation PHASE3
Mar 2020 — Apr 2020 [monthly]

Enrolling By Invitation PHASE3
Feb 2020 — Mar 2020 [monthly]

Enrolling By Invitation PHASE3
Jan 2020 — Feb 2020 [monthly]

Enrolling By Invitation PHASE3
Dec 2019 — Jan 2020 [monthly]

Enrolling By Invitation PHASE3
Nov 2019 — Dec 2019 [monthly]

Enrolling By Invitation PHASE3

First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Biopharma SRL

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Baton Rouge, United States , Beckley, United States , Boise, United States , Brno, Czechia , Brooklyn, United States , Charlotte, United States , Dayton, United States , Duncansville, United States , Elblag, Poland and 31 more locations